Gina C. Schatteman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Gina C. Schatteman has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
Chunhua Jiao
2 shared publicationsBarbara A. Christy
Anatomy and Cell Biology, University of Iowa, Iowa City, Iowa, USA2Molecular Medicine, University of Texas Health Science Center, San Antonio, Texas, USA
1 shared publicationC. Jiao
Integrative Physiology FH412, University of Iowa, Iowa, IA 52242, USA
1 shared publicationHeather D. Hanlon
Anatomy and Cell Biology, University of Iowa, Iowa City, Iowa, USA2Molecular Medicine, University of Texas Health Science Center, San Antonio, Texas, USA
1 shared publicationMartine Dunnwald
1 shared publicationNing Ma
Department of Exercise Science, University of Iowa, Iowa City, Iowa, USA
1 shared publication
Latest Publications
- 1 January 2007
- Published by American Physiological Society in American Journal of Physiology-Heart and Circulatory Physiology
- Vol. 292 (1) , H1-H18
Biology of bone marrow-derived endothelial cell precursors
Over the past decade, the old idea that the bone marrow contains endothelial cell precursors has become an area of renewed interest. While some still believe that there are no endothelial precursors in the blood, even among those who do, there is no consensus as to what they are or what they do. In this review, we describe the problems in identifying endothelial cells and conclude that expression of endothelial nitric oxide synthase may be the most reliable antigenic indicator of the phenotype. The evidence for two different classes of endothelial precursors is also presented. We suggest that, though there is no single endothelial cell precursor, we may be able to use these phenotypic variations to our advantage in better understanding their biology. We also discuss how a variety of genetic, epigenetic, and methodological differences can account for the seemingly contradictory findings on the physiological relevance of bone marrow-derived precursors in normal vascular maintenance and in response to injury. Data on the impact of tumor type and location on the contribution of bone marrow-derived cells to the tumor vasculature are also presented. These data provide hope that we may ultimately be able to predict those tumors in which bone marrow-derived cells will have a significant contribution and design therapies accordingly. Finally, factors that regulate bone marrow cell recruitment to and function in the endothelium are beginning to be identified, and several of these, including stromal derived factor 1, monocyte chemoattractant factor-1, and vascular endothelial growth factor are discussed.
- 1 January 2007
- Published by American Physiological Society in American Journal of Physiology-Heart and Circulatory Physiology
- Vol. 292 (1) , H1-H18
Biology of bone marrow-derived endothelial cell precursors
Over the past decade, the old idea that the bone marrow contains endothelial cell precursors has become an area of renewed interest. While some still believe that there are no endothelial precursors in the blood, even among those who do, there is no consensus as to what they are or what they do. In this review, we describe the problems in identifying endothelial cells and conclude that expression of endothelial nitric oxide synthase may be the most reliable antigenic indicator of the phenotype. The evidence for two different classes of endothelial precursors is also presented. We suggest that, though there is no single endothelial cell precursor, we may be able to use these phenotypic variations to our advantage in better understanding their biology. We also discuss how a variety of genetic, epigenetic, and methodological differences can account for the seemingly contradictory findings on the physiological relevance of bone marrow-derived precursors in normal vascular maintenance and in response to injury. Data on the impact of tumor type and location on the contribution of bone marrow-derived cells to the tumor vasculature are also presented. These data provide hope that we may ultimately be able to predict those tumors in which bone marrow-derived cells will have a significant contribution and design therapies accordingly. Finally, factors that regulate bone marrow cell recruitment to and function in the endothelium are beginning to be identified, and several of these, including stromal derived factor 1, monocyte chemoattractant factor-1, and vascular endothelial growth factor are discussed.
- 26 September 2006
- Published by Springer Nature in Diabetologia
- Vol. 49 (11) , 2786-2789
The chemokine (C-X-C motif) receptor 4 inhibitor AMD3100 accelerates blood flow restoration in diabetic mice
- 26 September 2006
- Published by Springer Nature in Diabetologia
- Vol. 49 (11) , 2786-2789
The chemokine (C-X-C motif) receptor 4 inhibitor AMD3100 accelerates blood flow restoration in diabetic mice
- 3 November 2005
- Published by Oxford University Press (OUP) in Stem Cells
- Vol. 24 (3) , 717-721
Old Bone Marrow Cells Inhibit Skin Wound Vascularization
Local injection of hematopoietic stem cell–enriched cells, including mouse lin− cells, accelerates vascularization in animal injury models, apparently by release of angiogenic factors. Locally injected lin− cells from nondiabetic mice dramatically improve, but those from obese diabetic mice inhibit vascular growth in obese diabetic mouse skin wounds. Because of similarities between diabetes and aging and because autologous bone marrow–derived cells are currently being tested in clinical trials involving older patients, we investigated the effects of old lin− cells on skin wound vascularization in nondiabetic and obese diabetic mice. Treatment with old lin− bone marrow cells resulted in decreased vessel size and numerical density, leading to profoundly reduced vascular volume density in wounds of non-diabetic and diabetic mice. Our data suggest that bone marrow–derived cells may be poor candidates for therapeutic use in older patients and could actually harm them.
- 3 November 2005
- Published by Oxford University Press (OUP) in Stem Cells
- Vol. 24 (3) , 717-721
Old Bone Marrow Cells Inhibit Skin Wound Vascularization
Local injection of hematopoietic stem cell–enriched cells, including mouse lin− cells, accelerates vascularization in animal injury models, apparently by release of angiogenic factors. Locally injected lin− cells from nondiabetic mice dramatically improve, but those from obese diabetic mice inhibit vascular growth in obese diabetic mouse skin wounds. Because of similarities between diabetes and aging and because autologous bone marrow–derived cells are currently being tested in clinical trials involving older patients, we investigated the effects of old lin− cells on skin wound vascularization in nondiabetic and obese diabetic mice. Treatment with old lin− bone marrow cells resulted in decreased vessel size and numerical density, leading to profoundly reduced vascular volume density in wounds of non-diabetic and diabetic mice. Our data suggest that bone marrow–derived cells may be poor candidates for therapeutic use in older patients and could actually harm them.
- Open Access
- 15 August 2000
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 106 (4) , 571-578
Blood-derived angioblasts accelerate blood-flow restoration in diabetic mice
Endothelial cell progenitors, angioblasts, have been detected in the peripheral blood of adult humans, mice, and rabbits. These cells have been shown to incorporate into the endothelium of newly forming blood vessels in pathological and nonpathological conditions. Here we investigated the possibility that the CD34-expressing leukocytes (CD34+ cells) that appear to be enriched for angioblasts could be used to accelerate the rate of blood-flow restoration in nondiabetic and diabetic mice undergoing neovascularization due to hindlimb ischemia. CD34+ cells did not accelerate the restoration of flow in nondiabetic mice, but dramatically increased it in diabetic mice. Furthermore, CD34+ cells derived from type 1 diabetics produced fewer differentiated endothelial cells in culture than did their type 2 diabetic– or nondiabetic-derived counterparts. In vitro experiments suggest that hyperglycemia per se does not alter the ability of angioblasts to differentiate or of angioblast-derived endothelial cells to proliferate. In contrast, hyperinsulinemia may enhance angioblast differentiation but impair angioblast-derived endothelial cell survival or proliferation. Our findings suggest that CD34+ cells may be a useful tool for therapeutic angiogenesis in diabetics.
- 15 August 2000
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 106 (4) , 571-578
Open AccessBlood-derived angioblasts accelerate blood-flow restoration in diabetic mice
Endothelial cell progenitors, angioblasts, have been detected in the peripheral blood of adult humans, mice, and rabbits. These cells have been shown to incorporate into the endothelium of newly forming blood vessels in pathological and nonpathological conditions. Here we investigated the possibility that the CD34-expressing leukocytes (CD34+ cells) that appear to be enriched for angioblasts could be used to accelerate the rate of blood-flow restoration in nondiabetic and diabetic mice undergoing neovascularization due to hindlimb ischemia. CD34+ cells did not accelerate the restoration of flow in nondiabetic mice, but dramatically increased it in diabetic mice. Furthermore, CD34+ cells derived from type 1 diabetics produced fewer differentiated endothelial cells in culture than did their type 2 diabetic– or nondiabetic-derived counterparts. In vitro experiments suggest that hyperglycemia per se does not alter the ability of angioblasts to differentiate or of angioblast-derived endothelial cells to proliferate. In contrast, hyperinsulinemia may enhance angioblast differentiation but impair angioblast-derived endothelial cell survival or proliferation. Our findings suggest that CD34+ cells may be a useful tool for therapeutic angiogenesis in diabetics.